NeuroVigil
Latest round
- Series B
Last raised
- May 2015
Total raised
- $0.3M
Investors
- 3
About NeuroVigil
NeuroVigil, founded in the US, is dedicated to pioneering neurotechnology solutions. The company has not undergone any significant pivots but operates as an independent entity. The founder's background is not specified.Neurovigil, Inc. specializes in advanced neurotechnology, primarily through its flagship product, the iBrain, a portable device designed to monitor brain activity using a single-electrode electroencephalogram (EEG) cap. The iBrain enables users to record brainwave data during sleep, facilitating the early diagnosis of neurological disorders such as Alzheimer's, Parkinson's, and sleep apnea. By employing the SPEARS (Sleep Parametric EEG Automated Recognition System Algorithm), this technology allows for real-time analysis of brain activity, significantly enhancing traditional research methodologies in neuroscience and psychopharmacology. Neurovigil's target clientele includes pharmaceutical companies and research institutions involved in the development of CNS (central nervous system) therapies, primarily focusing on markets in North America and Europe.Neurovigil's revenue model is centered on partnerships with pharmaceutical companies and research institutions that utilize its iBrain technology in clinical trials and research initiatives. Transactions typically occur on a subscription basis, where clients engage Neurovigil for a specified period, gaining access to the iBrain devices and analysis services for their studies. These arrangements often include comprehensive support services that ensure effective integration of the technology into existing research frameworks. The revenue structure is designed to facilitate ongoing collaborations, emphasizing long-term relationships with clients committed to advancing neurological research. The company is currently working on new iterations of the iBrain device and anticipates launching these advancements in the near future. Additionally, it aims to expand its market reach into Europe and Asia by 2025, targeting pharmaceutical companies and research institutions that focus on central nervous system disorders.
Who invested in NeuroVigil
3 investors across 2 rounds
See all investors in NeuroVigil
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about NeuroVigil
Who invested in NeuroVigil?
NeuroVigil has 3 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has NeuroVigil raised?
NeuroVigil has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did NeuroVigil last raise money?
NeuroVigil's most recent round on record is a Series B, in May 2015.
What does NeuroVigil do?
NeuroVigil, founded in the US, is dedicated to pioneering neurotechnology solutions.
Where is NeuroVigil headquartered?
NeuroVigil is headquartered in US.
Which VCs invest in companies like NeuroVigil?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Kleiner Perkins and Lightspeed Venture Partners back healthcare companies at NeuroVigil's stage. Their profiles are linked below.
VCs backing healthcare startups at Series B
Raising like NeuroVigil? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.